The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1469-1476

  Johnson, Dennis R ^a   Finch, Rick A ^a   Ping Lin, Z ^a   Zeiss, Caroline J ^a   Sartorelli, Alan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST CULTURE; GASTROINTESTINAL TOXICITY; GENE; KNOCKOUT GENE; KNOCKOUT MOUSE; MALE; MDR1A GENE; MDR1B GENE; MOUSE; MRP1 GENE; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CROSSES, GENETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FEMALE; GENES, MDR; MALE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; VINCRISTINE;

EID: 0035866385     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
2. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
3. Structural, mechanistic, and clinical aspects of MRP1
4. The multidrug resistance protein family
5. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver
6. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals
7. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins
8. r 190,000 multidrug resistance protein (MRP): Evidence for co-transport with reduced glutathione
9. Disruption of the murine mrp (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione
10. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins
11. Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and increased sensitivity to drugs
12. MDR1/P-glycoprotein in haematological neoplasms
13. MDR1 gene expression in solid tumors
14. Clinical multidrug resistance in cancer: A multifactorial problem
15. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated proteins
16. Double knockout of the MRP gene leads to increased drug sensitivity in vitro
17. Multidrug resistance protein 1 protects the oropharyngeal mucosa layer and the testicular tubules against drug-induced damage
18. Immunocytochemical localization of p170 at the plasma membrane of multidrug-resistant human cells
19. MDR1 gene expression in solid tumors
20. Expression of the multidrug resistance associated-protein (MRP) gene in non-small-cell lung cancer
21. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers
22. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer
23. Multidrug resistance protein in recurrent breast cancer
24. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer
25. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
26. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma
27. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein
28. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response
29. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
30. Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance
31. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
32. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity
33. Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146
34. Multidrug resistance-associated protein subfamily transporters and drug resistance
35. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP)
36. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P
37. The nature of cytotoxic drug-induced cell death in murine intestinal crypts
38. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
39. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
40. ATP dependent 17(β-D-glucuronide) transport by multidrug resistance protein: Inhibition by cholestatic steroids
41. VB/N: An inbred mouse strain preferable for transgenic analyses
42. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
43. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive stargardt macular dystrophy
44. Extensive contribution of the multidrug transporters P-glycoprotein and mrp1 to basal drug resistance
45. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells